4-((6-(4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)-6-oxohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

ID: ALA5281482

Max Phase: Preclinical

Molecular Formula: C43H48N10O7

Molecular Weight: 816.92

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCN(C(=O)CCCCCNc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)cn3)nc2n(C2CCCC2)c1=O

Standard InChI: InChI=1S/C43H48N10O7/c1-25-30-24-46-43(49-38(30)52(27-9-5-6-10-27)41(59)36(25)26(2)54)47-33-16-14-28(23-45-33)50-19-21-51(22-20-50)35(56)13-4-3-7-18-44-31-12-8-11-29-37(31)42(60)53(40(29)58)32-15-17-34(55)48-39(32)57/h8,11-12,14,16,23-24,27,32,44H,3-7,9-10,13,15,17-22H2,1-2H3,(H,48,55,57)(H,45,46,47,49)

Standard InChI Key: SBQOAVDBMVISJT-UHFFFAOYSA-N

Molfile:

 
     RDKit          2D

 60 67  0  0  0  0  0  0  0  0999 V2000
   -8.3538    1.5130    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3538    0.6880    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6394    0.2755    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9250    0.6880    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9250    1.5130    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6394    1.9255    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6394    2.7503    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0353    3.3050    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3673    4.0645    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1683    3.9837    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3536    3.1626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2124    1.9238    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4976    1.5114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4976    0.6905    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2073    0.2739    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7834    1.9237    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0691    1.5114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3548    1.9236    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6431    1.5118    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6431    0.6868    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3530    0.2751    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0691    0.6831    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9288    0.2744    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2146    0.6868    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5004    0.2744    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5004   -0.5502    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2146   -0.9625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9288   -0.5502    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2138   -0.9625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9280   -0.5502    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6423   -0.9625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3565   -0.5502    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0707   -0.9625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7850   -0.5502    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4992   -0.9625    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.4992   -1.7873    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2126   -2.1999    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2126   -3.0221    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4982   -3.4346    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7819   -3.0257    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7819   -2.2015    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9925   -3.2679    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4834   -2.6031    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.0150   -1.9513    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2284   -1.1547    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.3082   -2.6031    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7206   -3.3174    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5453   -3.3174    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9576   -2.6032    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5452   -1.8889    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.7206   -1.8889    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3082   -1.1747    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.7823   -2.6032    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.2060   -4.0645    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.2138   -1.7873    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6394   -0.5491    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.0681    0.2756    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.0681   -0.5490    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7823    0.6880    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.0681    1.9254    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  1  6  1  0
  7  6  1  0
  7  8  1  0
  8  9  1  0
 10  9  1  0
 11 10  1  0
  7 11  1  0
  5 12  1  0
 13 12  2  0
 14 13  1  0
 15 14  2  0
  4 15  1  0
 13 16  1  0
 16 17  1  0
 18 17  2  0
 19 18  1  0
 20 19  2  0
 21 20  1  0
 22 21  2  0
 17 22  1  0
 20 23  1  0
 24 23  1  0
 25 24  1  0
 26 25  1  0
 27 26  1  0
 28 27  1  0
 23 28  1  0
 26 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 35 36  1  0
 37 36  2  0
 38 37  1  0
 39 38  2  0
 40 39  1  0
 41 40  2  0
 36 41  1  0
 38 42  1  0
 42 43  1  0
 44 43  1  0
 37 44  1  0
 44 45  2  0
 46 43  1  0
 46 47  1  0
 47 48  1  0
 48 49  1  0
 49 50  1  0
 50 51  1  0
 46 51  1  0
 51 52  2  0
 49 53  2  0
 42 54  2  0
 29 55  2  0
  3 56  1  0
  2 57  1  0
 57 58  2  0
 57 59  1  0
  1 60  2  0
M  END

Associated Targets(Human)

CDK4 Tclin Protein cereblon/Cyclin-dependent kinase 4 (68 Activities)

Discover Target: CDK4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CDK6 Tclin Protein cereblon/Cyclin-dependent kinase 6 (113 Activities)

Discover Target: CDK6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type:	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 816.92	Molecular Weight (Monoisotopic): 816.3707	AlogP: 4.28	#Rotatable Bonds: 13
Polar Surface Area: 208.90	Molecular Species: NEUTRAL	HBA: 14	HBD: 3
#RO5 Violations: 2	HBA (Lipinski): 17	HBD (Lipinski): 3	#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.15	CX Basic pKa: 3.53	CX LogP: 3.64	CX LogD: 3.64
Aromatic Rings: 4	Heavy Atoms: 60	QED Weighted: 0.10	Np Likeness Score: -0.91

References

1. Wang C, Zhang Y, Wu Y, Xing D.. (2021) Developments of CRBN-based PROTACs as potential therapeutic agents., 225 [PMID:34411892] [10.1016/j.ejmech.2021.113749]
2. Gray, N S NS and 12 more authors. 1998-07-24 Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. [PMID:9677190]
3. Kubo, A A and 9 more authors. 1999-12 The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. [PMID:10632371]
4. Soni, R R and 7 more authors. 2000-09-07 Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. [PMID:10973815]
5. Lane, M E ME and 9 more authors. 2001-08-15 A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. [PMID:11507069]
6. Tavares, Francis X FX and 7 more authors. 2004-09-09 N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy. [PMID:15341487]
7. Fry, David W DW and 10 more authors. 2004-11 Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. [PMID:15542782]
8. Pennati, Marzia M and 12 more authors. 2005-09 Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. [PMID:16170024]
9. Sridhar, Jayalakshmi J, Akula, Nagaraju N and Pattabiraman, Nagarajan N. 2006-03-24 Selectivity and potency of cyclin-dependent kinase inhibitors. [PMID:16584130]
10. DePinto, Wanda W and 19 more authors. 2006-11 In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. [PMID:17121911]
11. Joshi, Kalpana S KS and 7 more authors. 2007-03 In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. [PMID:17363486]
12. Squires, Matthew S MS and 7 more authors. 2009-02 Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. [PMID:19174555]
13. Cirstea, D D and 15 more authors. 2013-12 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. [PMID:23807770]
14. Gelbert, Lawrence M LM and 16 more authors. 2014-10 Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. [PMID:24919854]
15. Paiva, Cody C and 8 more authors. 2015 Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. [PMID:26606677]
16. Bisi, John E JE, Sorrentino, Jessica A JA, Roberts, Patrick J PJ, Tavares, Francis X FX and Strum, Jay C JC. 2016-05 Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. [PMID:26826116]
17. Klaeger, Susan S and 47 more authors. 2017-12-01 The target landscape of clinical kinase drugs. [PMID:29191878]
18. Wang, Yan Y and 10 more authors. 2018-03-01 Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships. [PMID:29429832]
19. Tear, Westley F and 16 more authors. 2020-01-23 Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-b]pyridazines for the Treatment of Human African Trypanosomiasis. [PMID:31846577]
20. Wu, Tizhi and 6 more authors. 2020-11-25 Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. [PMID:32866383]

4-((6-(4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)-6-oxohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source